A Phase 4 interventional study of Brodalumab and Fumaric acid esters in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 30 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by LEO Pharma · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing brodalumab in Psoriasis — none open to participants now, 1 under way, none of them phase 3. brodalumab · Psoriasis.
Among the 26 studies testing brodalumab in Psoriasis, this one is the 6th largest by enrollment, is one of 3 that started in 2017, is one of 10 in phase 4, and was the 16th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 26 studies testing brodalumab in Psoriasis is open now. The open studies under Psoriasis, anywhere →
brodalumab: first FDA approval 2017 (SILIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2017.
This study's enrollment of 210 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 132 across the 26 interventional studies. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 26 have an industry lead sponsor. The 9 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 25th largest by enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2017, is one of 7 in phase 4, and was the 67th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing brodalumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis.
Fumaric acid esters have been selected as the comparator because it is an established systemic treatment of psoriasis in Germany.
A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with investigator-blinded efficacy assessments
Main Criteria for Inclusion:
Main Criteria for Exclusion:
Washouts and non-permitted drugs:
Subjects with any of the following laboratory abnormalities at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Kyntheum® (brodalumab) pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections. First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
Biological: Brodalumab
Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt) Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt) Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label.
Drug: Fumaric acid esters
Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA). Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.
Also known as: Kyntheum®
Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
Also known as: Fumaderm®
Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).
Time frame: Baseline to Week 24
Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24
sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation. Static Physician's Global Assessment is a scale ranging rom 0 (clear skin) to 5 (severe disease).
Time frame: Baseline to Week 24
Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).
Time frame: Baseline to Week 24
Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).
Time frame: Baseline to Week 24
Change From Baseline at Week 24 in PASI Score
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative change in PASI score means that the PASI score was lower at the time of data collection.
Time frame: Baseline to Week 24
Percent Change From Baseline in PASI Score at Week 24
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative value in the percent change from baseline that the PASI score was lower at the time of data collection.
Time frame: Baseline to Week 24
Change From Baseline at Week 24 in Affected Body Surface Area (BSA)
The surface area of the participant's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA. Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%). A negative value in the percent change from baseline that the affected BSA was lower at the time of data collection.
Time frame: Baseline to Week 24
Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1)
The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.
Time frame: Week 24
PSI Total Score of 0 at Week 24
The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.
Time frame: Week 24
Number of Symptom-free Days From Randomisation to Week 24
The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.
Time frame: Baseline to Week 24
Burden of Symptoms
Burden of symptoms was assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment. The AUC for the PSI total score was calculated for each participant using the standard trapezoidal rule. The AUC was normalised by dividing it with the time from baseline to the last available assessment of the PSI total score. The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.
Time frame: Baseline to Week 24
Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score
DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.
Time frame: Baseline to Week 24
DLQI Total Score of 0 or 1 at Week 24
DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.
Time frame: Week 24
Change From Baseline at Week 24 in NAPSI Total Score
The Nail Psoriasis Severity Index (NAPSI) grades nails by first dividing the nail area with imaginary horizontal and vertical lines into 4 quarters. The following 8 clinical features of nail psoriasis are then scored based on the number of quarters in which the feature is present (0 to 4) to arrive at a NAPSI score of 0 to 32 for each nail: * Pitting. * Leukonychia. * Red spots in lunula. * Nail plate crumbling. * Oil drop (salmon patch) discoloration. * Onycholysis. * Nail bed hyperkeratosis. * Splinter haemorrhages. A negative change in NAPSI score means that the NAPSI score was lower at the time of data collection.
Time frame: Baseline to Week 24
| Milestone | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Started | 105 | 105 |
| Completed | 91 | 58 |
| Not completed | 14 | 47 |
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 | 85 | 40 |
sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation. Static Physician's Global Assessment is a scale ranging rom 0 (clear skin) to 5 (severe disease).
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24 | 68 | 21 |
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24 | 69 | 23 |
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24 | 42 | 9 |
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative change in PASI score means that the PASI score was lower at the time of data collection.
| score on a scale | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Change From Baseline at Week 24 in PASI Score | -15.69 ± 0.59 | -12.62 ± 0.67 |
The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative value in the percent change from baseline that the PASI score was lower at the time of data collection.
| percent change in PASI | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Percent Change From Baseline in PASI Score at Week 24 | -90.03 ± 2.25 | -73.67 ± 2.63 |
The surface area of the participant's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA. Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%). A negative value in the percent change from baseline that the affected BSA was lower at the time of data collection.
| percent change | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Change From Baseline at Week 24 in Affected Body Surface Area (BSA) | -20.82 ± 1.48 | -11.91 ± 1.48 |
The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1) | 15 | 13 |
The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| PSI Total Score of 0 at Week 24 | 5 | 3 |
The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.
| days | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Number of Symptom-free Days From Randomisation to Week 24 | 0.44 ± 0.8 | 0.42 ± 1.3 |
Burden of symptoms was assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment. The AUC for the PSI total score was calculated for each participant using the standard trapezoidal rule. The AUC was normalised by dividing it with the time from baseline to the last available assessment of the PSI total score. The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.
| score on a scale | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Burden of Symptoms | 6.00 ± 0.54 | 10.92 ± 0.55 |
DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.
| score on a scale | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score | -16.67 ± 0.61 | -14.10 ± 0.70 |
DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.
| Participants | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| DLQI Total Score of 0 or 1 at Week 24 | 70 | 27 |
The Nail Psoriasis Severity Index (NAPSI) grades nails by first dividing the nail area with imaginary horizontal and vertical lines into 4 quarters. The following 8 clinical features of nail psoriasis are then scored based on the number of quarters in which the feature is present (0 to 4) to arrive at a NAPSI score of 0 to 32 for each nail: * Pitting. * Leukonychia. * Red spots in lunula. * Nail plate crumbling. * Oil drop (salmon patch) discoloration. * Onycholysis. * Nail bed hyperkeratosis. * Splinter haemorrhages. A negative change in NAPSI score means that the NAPSI score was lower at the time of data collection.
| score on a scale | Brodalumab | Fumaric Acid Esters |
|---|---|---|
| Change From Baseline at Week 24 in NAPSI Total Score | -2.97 ± 0.54 | -1.26 ± 0.57 |
Collected over From the first day of investigational medicinal product (IMP) administration and until 32 weeks later for brodalumab and 26 weeks later for fumaric acid esters. The difference in collection periods was due to the different half-lives of the IMPs.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brodalumab 210 mg | 0/104 (0%) | 3/104 (2.9%) | 66/104 (63.5%) |
| Fumaric Acid Ester | 0/102 (0%) | 1/102 (1%) | 90/102 (88.2%) |
| Event | Brodalumab 210 mg | Fumaric Acid Ester |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/104 | 1/102 |
| Reactive gastropathyGastrointestinal disorders | 1/104 | 0/102 |
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/104 | 0/102 |
| Stasis dermatitisSkin and subcutaneous tissue disorders | 1/104 | 0/102 |
| Event | Brodalumab 210 mg | Fumaric Acid Ester |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/104 | 59/102 |
| Viral upper respiratory tract infectionInfections and infestations | 35/104 | 21/102 |
| FlushingVascular disorders | 0/104 | 29/102 |
| Abdominal pain upperGastrointestinal disorders | 2/104 | 28/102 |
| LymphopeniaBlood and lymphatic system disorders | 2/104 | 14/102 |
| HeadacheNervous system disorders | 13/104 | 12/102 |
| Abdominal painGastrointestinal disorders | 2/104 | 11/102 |
| NauseaGastrointestinal disorders | 6/104 | 9/102 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/104 | 4/102 |
| OverdoseInjury, poisoning and procedural complications | 8/104 | 0/102 |
| Age, Categorical(Participants) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 96 | 97 | 193 |
| >=65 years | 9 | 8 | 17 |
| Sex: Female, Male(Participants) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| Female | 32 | 33 | 65 |
| Male | 73 | 72 | 145 |
| Ethnicity (NIH/OMB)(Participants) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 100 | 103 | 203 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 104 | 105 | 209 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| Germany | 105 | 105 | 210 |
| Height(cm) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| Mean | 175 ± 9.6 | 176 ± 9.8 | 175 ± 9.7 |
| Weight(kg) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| Mean | 87.8 ± 20.4 | 86.6 ± 21.1 | 87.2 ± 20.7 |
| Mean weight in participants weighing <100 kg(kg) | Brodalumab | Fumaric Acid Esters | Total |
|---|---|---|---|
| Mean | 78.4 ± 11.9 | 77.2 ± 12.8 | 77.8 ± 12.4 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Jan 2019, 14 months.
Results were first posted in Feb 2020, 1 year after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brodalumab